MedTrace Logo

Trial To Evaluate RPh201 In Treatment Of Partial Thickness Burn

NCT01455480 · Status: WITHDRAWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL

Last updated 2016-12-06

No results posted yet for this study

Summary

The objective of this Trial is to evaluate the performance of RPh201 as a treatment for the healing of partial thickness burns. It is further postulated that deep second degree lesions will benefit from the RPh201 treatment promoting granulation and epithelialization as well as wound closure.

Conditions

  • Second Degree Burn Less Than 5%TBSA
  • Partial Thickness Burn

Interventions

DRUG

RPh201, botanical drug product

topical

Sponsors & Collaborators

  • Regenera Pharma Ltd

    lead INDUSTRY

Principal Investigators

  • Eyal Winkler, Dr. MD · Clinic of the The Burn Unit, The Department of Plastic & Reconstructive Surgery and Medical Research Infrastructure Development and Health Services Fund by Chaim Sheba Medical Center Tel Hashomer, Israel

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-12-31
Primary Completion
2011-12-31
Completion
2011-12-31

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01455480 on ClinicalTrials.gov